January 6, 2012 |
In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back. The study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.
September 12, 2012 |
Kathy Bates has beaten cancer yet again, she revealed Wednesday. "Hey All, sorry for the long silence," she said in a two-part Twitter message. "I was diagnosed with breast cancer 2 months ago & am recovering from a double mastectomy. ... I don't miss my breasts as much as I miss Harry's Law. ;-) Thanks for all the sweet tweets. Y'all kept me going. " The "Titanic" actress was diagnosed with ovarian cancer in 2003, an experience she discussed in the video above, for the Ovarian Cancer National Alliance.
February 2, 2012 |
The long-debunked idea that abortions can contribute to breast cancer is reappearing amid the outpouring of comments this week on Susan G. Komen for the Cure's decision to stop funding Planned Parenthood breast-health programs. Here's one comment on Komen's Facebook page: "Also! Breast cancer is linked to abortions!!! More and more studied are pointing to abortions for a huge risk factor for BC, why should SGK support something that raises the chances of what they wasn't destroyed?
December 10, 2010 |
The breast cancer drug pertuzumab when added to Herceptin improved the treatment of women with early-stage, HER-2 positive breast cancer, researchers reported Friday at the annual meeting of the San Antonio Breast Cancer Symposium . Pertuzumab is an experimental monoclonal antibody. In the study, 417 women received monoclonal antibody drug therapy before having surgery to remove the tumor. Some women also underwent chemotherapy. Adding pertuzumab to Herceptin -- which is also known by the generic name trastuzumab -- along with the chemotherapy drug docetaxel led to a tumor eradication rate of 46%. That is 50% better than the tumor eradication rate achieved with the standard therapy of docetaxel and Herceptin combined, said the authors of the paper, from the National Cancer Institute in Milan, Italy.
October 14, 2011 |
Slogging through all the pink-themed products, promotions and publicity centered on breast cancer awareness month, it's been tough to find anything that stood out. But we did. We found this video from the Canadian-based organization Rethink Breast Cancer advertising an app that reminds you to do a breast self-exam. But this is no ordinary breast cancer video, and this is not your everyday app. The video begins with "Dr. " Rothaford Gray talking about how many women aren't checking regularly for breast cancer.
October 28, 2010 |
For many women, the fight against breast cancer is public, with support from friends and family and frequent discussions with healthcare professionals about side effects and treatment. But part of that fight is intensely private -- rarely more so than when it affects their sex life. Certain chemotherapy drugs send women into early menopause within a few months. That, coupled, with hair loss and disfiguring mastectomies, leave some breast cancer survivors struggling to be intimate again, a new study finds.
September 30, 2010 |
There may be few pregnancy nightmares worse than finding a lump in one's breast, given the dueling fears that if it's cancer, treatment could harm the developing fetus, while delay and pregnancy hormones could fuel a tumor's growth. But a new study finds that pregnant women treated for breast cancer are more likely to survive their ordeal than breast cancer patients of the same age who were not pregnant when their cancer was diagnosed. Five years after their diagnosis, almost 74% of the women diagnosed with breast cancer during pregnancy were still alive.
November 28, 2012 |
A new genetic test may help determine whether a small tumor in the breast is likely to turn in to full-blown breast cancer, according to a study published Wednesday in the Journal of the National Cancer Institute. The small tumor, called a ductal carcinoma in-situ, or DCIS, resides in the milk ducts and is generally considered pre-cancerous. But according to the study, DCIS lesions left untreated will eventually progress to breast cancer in about 50% of patients. The lesions, which tend to be small and only detectable via mammogram, have become increasingly common as mammography has become more widespread.